SOHO 2025 | Unmet needs and current perspectives in high-risk MCL

So I think one of the key big unmet needs at this point is what we consider high-risk mantle cell lymphoma. I think as we’ll hear here at this meeting there’ll be a lot of discussion and debate on what actually qualifies as high-risk mantle cell lymphoma and then thereafter what do we do to sort of manage and treat these patients. We have some hints of data from a lot of the frontline studies that have been conducted in the last several years such as TRIANGLE and ECHO and even some of the novel treatments such as BOVen to see how novel treatments have impacted patients with high-risk mantle cell lymphoma. We see some disparate sort of data sets based on some of the high-risk features. It does appear that use of the BTK inhibitors has improved outcomes for those with p53 mutations but ideally if we look at maybe blastoid pleomorphic patients it does appear that there is still some more unmet need in that patient area and sort of maybe more needs to be done. Additionally, with those studies that I mentioned, TRIANGLE and ECHO, with the moving of BTK inhibitors into the frontline space, I think the question comes, what do we do when those medications unfortunately stop working for our patients? And what is the next thing that can help salvage these patients? Because not all of these patients will be able to make it to CAR T-cell therapy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.